The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II

The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II

IntroductionPost-hoc analyses of the BIPARK-I and II trials previously demonstrated that opicapone (OPC) 50 mg was efficacious over the whole trajectory of motor fluctuation evolution in patients with Parkinson's disease (PD) and end-of-dose motor fluctuations, with enhanced efficacy in patient...

Full description

Bibliographic Details
Main Authors: José-Francisco Rocha, Georg Ebersbach, Andrew Lees, Eduardo Tolosa, Joaquim J. Ferreira, Werner Poewe, Olivier Rascol, Fabrizio Stocchi, Angelo Antonini, Diogo Magalhães, Helena Gama, Patrício Soares-da-Silva
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Neurology
Subjects:
catechol-O-methyltransferase inhibitor
levodopa
motor fluctuations
opicapone
Parkinson's disease
safety/tolerability
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2022.994114/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2022.994114/full

Similar Items